Nouscom presentation of a Late-Breaking Abstract on Translational Phase 1b data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, at AACR 2023 - Nouscom

Nouscom presentation of a Late-Breaking Abstract on Translational Phase 1b data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, at AACR 2023

By ef

Posted 11/10/2023

In Presentations

PRESENTATION TITLE: Nouscom presentation of a Late-Breaking Abstract on Translational Phase 1b data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, at AACR 2023

Read more

Recent Posts

Nouscom Raises €67.5 million ($72 million) in Oversubscribed  Series C Financing Round
Dr. Morena D’Alise (VP of Immunology) is presenting at the SITC Annual Meeting 2023, San Diego November 1-3
Dr. Elisa Scarselli (Nouscom CSO) invited speaker at EHTG European Hereditary Tumour Group 2023, Vilnius September 28 – October 1st
Dr. Elisa Scarselli (CSO) invited speaker at Vaccines Europe 2023, Berlin September 13-15

error: Content is protected !!!